Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma
Study Details
Study Description
Brief Summary
This is a randomized unblinded Phase II clinical trial evaluating the impact of intensive antihypertensive control (targeted to the 50-75th percentile for age, sex, and height) compared to conventional antihypertensive control (targeted to the 90-95th percentile for age, sex, and height) on the incidence of radiographically extensive osteonecrosis in children and young adults receiving treatment for newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL).
Primary Objective
- Compare the frequency of radiographically extensive osteonecrosis in patients receiving intensive compared to conventional antihypertensive therapy.
Secondary Objectives
-
Evaluate the efficacy of intensive antihypertensive control compared to conventional antihypertensive control in the prevention of clinically significant (CTCAE Grade 2 or higher) and radiologically extensive osteonecrosis, overall and stratified by joints.
-
Compare the frequency of clinically significant and radiographically extensive osteonecrosis in patients receiving antihypertensive therapy and historical controls.
-
Compare blood pressures achieved in intensive and conventional arms using both pressures obtained as part of routine patient care and ambulatory blood pressure monitoring.
-
Compare levels of vascular dysfunction as measured physiologically, radiographically, and in blood samples in patients receiving intensive compared to standard antihypertensive therapy.
Exploratory Objectives
-
Identify predictive patterns of blood biomarkers which identify patients at high- risk of developing clinically significant osteonecrosis.
-
Identify MRI findings during late induction which correlate with osteonecrosis lesions seen during reinduction.
-
Identify patterns of diurnal blood pressure variation as measured by ambulatory blood pressure monitoring associated with the later development of osteonecrosis.
-
Compare induction blood pressure control and intervention arm to echocardiographic changes at reinduction II.
-
Evaluate patient-reported, health-related quality of life in patients during induction and after 1.5 years of therapy when many experience the symptoms of osteonecrosis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Patient randomization will be stratified based on patient's location (Memphis vs. other), use of antihypertensives prior to randomization, and factors known to influence osteonecrosis risk, specifically sex and self-declared race (non-Hispanic white vs. other). A target systolic blood pressure range will be chosen for each participant based on their randomization arm, age, sex, and height.
Patients will be randomized on day 4 of induction therapy to either conventional or intensive blood pressure goals. Patients will be treated with antihypertensive therapy to achieve blood pressure control as indicated by their randomized arm. Therapy will be adjusted every 3-4 days as needed to achieve targeted control based on the mean of blood pressures obtained in that period. Treatment of hypertension to the target will continue until the completion of reinduction II therapy. Patients will be evaluated for osteonecrosis as indicated in their primary therapeutic protocol using MRI during reinduction II.
Patients will be asked to complete a symptom survey and a semi-structured interview.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intensive Antihypertensive Therapy Patients will begin Intensive antihypertensive therapy to achieve the targeted blood pressure (targeted to the 50-75th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II. |
Drug: Intensive Antihypertensive Therapy
Receives intensive antihypertensive therapy
Other Names:
Other: Symptom Survey
The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).
Other Names:
Other: Semi-structured interview
Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.
Other Names:
|
| Active Comparator: Conventional Antihypertensive Therapy Patients will begin Conventional antihypertensive therapy to achieve the targeted blood pressure (targeted to the 90-95th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II. |
Drug: Conventional Antihypertensive Therapy
Receives conventional antihypertensive therapy
Other Names:
Other: Symptom Survey
The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).
Other Names:
Other: Semi-structured interview
Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Extensive radiographic osteonecrosis [during reinduction II therapy, approximately 9 months into therapy.]
Involvement of >=30% of the epiphyseal surface of either the hip or knee by prospective MRI during reinduction II
Secondary Outcome Measures
- Rate of clinically significant osteonecrosis [any time during leukemia therapy, approximately 2.5 years]
CTCAE grade 2 or high osteonecrosis
- Rate of clinically significant osteonecrosis vs. historical control [any time during leukemia therapy, approximately 2.5 years]
CTCAE grade 2 or high osteonecrosis vs. Total 16 matched controls
- Blood pressure control on trial [first 9 months of therapy]
Comparison of repeated systolic and diastolic blood pressure measures between randomized treatment arms
- Biomarkers of vascular dysfunction - eNO synthetase (pg/mL) [3 weeks and 9 months into therapy]
Comparison between randomized treatment arms
- Biomarker of vascular dysfunction - Von Willebrand Factor (%) [3 weeks and 9 months into therapy]
Comparison between randomized treatment arms
- Biomarker of vascular dysfunction - TNF-alpha (pg/mL) [3 weeks and 9 months into therapy]
Comparison between randomized treatment arms
- Biomarker of vascular dysfunction - D-dimer (µg/mL) [3 weeks and 9 months into therapy]
Comparison between randomized treatment arms
- Biomarker of vascular dysfunction - PAI-1 (AU/mL) [3 weeks and 9 months into therapy]
Comparison between randomized treatment arms
- Biomarker of vascular dysfunction - E-selectin (ng/mL) [3 weeks and 9 months into therapy]
Comparison between randomized treatment arms
- Biomarker of vascular dysfunction - ICAM-1 (ng/mL) [3 weeks and 9 months into therapy]
Comparison between randomized treatment arms
- Biomarker of vascular dysfunction - Arterial elasticity (ml/mmHg) [3 weeks and 3 months into therapy]
Comparison between randomized treatment arms
- Biomarker of vascular dysfunction - Pulse Wave Velocity (m/sec) [3 weeks and 3 months into therapy]
Comparison between randomized treatment arms
- Magnetic resonance imaging (MRI) of hip and knee [3 weeks and 9 months into therapy]
Comparison between randomized treatment arms
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient is being treated for newly diagnosed acute lymphoblastic leukemia or lymphoma (ALL) on the TOT17 protocol. Patients do not need to be hypertensive to enroll.
-
Patient is 10 years of age or older at the time of enrollment on TOT17.
-
Patient has completed ≤ 4 days of protocol therapy (patients are eligible on Day 4 of TOT17 therapy).
Exclusion Criteria:
-
Moderate-severe renal dysfunction (glomerular filtration rate <45 ml/min/1.73m2).
-
Down's syndrome (germline Trisomy 21) or other syndrome resulting in growth delay or alterations in stature.
-
Chronic inability to ambulate. Patients with limitations in movement due to acute complications of leukemia/lymphoma are not excluded.
-
Permanent contraindication to MRI evaluation.
-
Participants who are pregnant or lactating. Males or females of reproductive potential must agree to use effective contraception for the duration of study participation.
-
Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Rady Children's Hospital | San Diego | California | United States | 92123 |
| 2 | St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital | Charlotte | North Carolina | United States | 28204 |
| 3 | St. Jude Children's Research Hospital | Memphis | Tennessee | United States | 38105 |
Sponsors and Collaborators
- St. Jude Children's Research Hospital
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Seth E. Karol, MD, St. Jude Children's Research Hospital
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- HYPERION
- 1K08CA250418
- NCI-2020-03603